88 results about "Scaffold protein" patented technology

Small molecule therapeutics can concentrate in distinct intracellular environments, some bounded by membranes, and others that may be formed by membrane-less biomolecular condensates. The chemical environments within biomolecular condensates have been proposed to differ from those outside these bodies, but the internal chemical environments of diverse condensates have yet to be explored. Here we use small molecule probes to demonstrate that condensates formed in vitro with the scaffold proteins of different biomolecular condensates harbor distinct chemical solvating properties. The chemical rules that govern selective partitioning in condensates, which we term condensate chemical grammar, can be ascertained by deep learning, allowing efficient prediction of the partitioning behavior of small molecules. The rules learned from in vitro condensates were adequate to predict the partitioning of small molecules into nucleolar condensates in living cells. Different biomolecular condensates harbor distinct chemical environments, that the chemical grammar of condensates can be ascertained by machine learning.

The present disclosure relates to a vesicle, the vesicle comprising: a scaffold protein, the scaffold protein being a nerve growth factor receptor or a fragment thereof; and a tag domain. The vesicles carry unique labels, engineered vesicles are separated through a large-scale purification process, and after quality control, the engineered vesicles can be used as standard substances and / or reference substances to be applied to different scenes.

A nanomedicine composition, preparation method, and use thereof, comprising: a negatively charged nanophospholipid disk and an antimicrobial compound; wherein the negatively charged nanophospholipid disk comprises a negatively charged phospholipid layer and a membrane scaffold protein, wherein the negatively charged phospholipid layer is formed by mixing a neutral phospholipid and a negatively charged phospholipid in a molar ratio of approximately 5:5-7:3. The nanomedicine composition provided herein reduces the toxicity of the antimicrobial compound while enhancing its antimicrobial efficacy, and has great potential for expansion into clinical applications.

The present invention relates to an exosome scaffold protein and the use thereof. PVR protein is used as an exosome scaffold protein to load effective substances, such that the loading capacity and the loading efficiency of the effective substances are improved. In addition, the exosome scaffold protein can also be used for loading larger and more structurally complex effective substances.

The invention relates to a combined bacterium system for efficiently synthesizing resveratrol and a method for synthesizing resveratrol, and belongs to the technical field of bioengineering and biosynthesis. The preparation method comprises the following steps: respectively connecting 4CL, STS and FCS with scaffold proteins, constructing recombinant expression vectors for expressing 4CL-SpyTag, STS-SpyCatcher and FCS-SpyTag, respectively introducing the recombinant expression vectors into escherichia coli, carrying out expression to obtain a compound enzyme connected with the scaffold proteins, and then carrying out self-assembly to obtain a multienzyme complex 4CL-SpyTag-STS-SpyCatcher and FCS-SpyTag-STS-SpyCatcher; the constructed recombinant engineering bacterium or enzyme complex is added into p-coumaric acid synthesized from agricultural wastes for further synthesis of resveratrol; the multi-enzyme complex constructed by the invention and the new method for synthesizing the resveratrol not only provide a new high-valued utilization approach for the lignin, but also realize efficient and high-yield synthesis of the resveratrol.

The invention provides an engineered exosome for treating sepsis as well as a construction method and application of the engineered exosome, and belongs to the technical field of biological medicines. The invention provides an engineered exosome for treating sepsis. The engineered exosome comprises the following fusion proteins: a first fusion protein formed by a cryptochrome 2 protein and an exosome scaffold protein, a lysosome targeting peptide, and a second fusion protein formed by a Caspase 1 protein recruitment protein structural domain and a cryptochrome 2 protein ligand. The cell level and animal level prove that the engineered exosome can efficiently and accurately inhibit secretion of inflammatory factors, reduce inflammatory response and pathological conditions in a sepsis animal model, and restore animal functions of the sepsis model to a certain extent. Therefore, the engineered exosome provided by the invention provides a new means for treating sepsis, and has great market popularization and application values.

The invention relates to the technical field of biology, in particular to a mirror image coupled protein nanoparticle conjugate and application thereof. The conjugate comprises: ii) a functional protein labeled by a first peptide tag, and ii) a scaffold protein labeled by a second peptide tag, the first peptide tag and the second peptide tag being composed of D-amino acid residues; the first peptide tag and the second peptide tag form a peptide partner pair, and the first peptide tag and the second peptide tag are coupled and combined through an isopeptide bond. The conjugate provided by the invention is easier to escape from the recognition of protease, can obviously prolong the half-life period in a biological system, is not easy to cause unnecessary immunoreaction, and has good biological stability and safety.

The present invention relates to an exosome scaffold protein and the use thereof. PVR protein is used as an exosome scaffold protein to load effective substances, such that the loading capacity and the loading efficiency of the effective substances are improved. In addition, the exosome scaffold protein can also be used for loading larger and more structurally complex effective substances.

The invention relates to a method for regulating and controlling the phase separation capacity of protein and application thereof. The method comprises the following steps: mixing a first protein element and a second protein element to obtain a mixture; detecting the phase separation capacity of the mixture; wherein the first protein element comprises an IDR structural domain of the scaffold protein, and the second protein element comprises a self-assembly structural domain of the scaffold protein or the IDR structural domain of the scaffold protein. According to the method, the IDR structural domain of the scaffold protein is used as the first protein element, the self-assembly structural domain of the scaffold protein or the IDR structural domain of the scaffold protein is used as the second protein element, and the first protein element and the second protein element interact with each other, so that the phase separation strength of the protein elements can be accurately regulated and controlled; and physical or chemical factor intervention is not needed, so that the compatibility between the regulation process and the normal physiological function of the cell is ensured. The method for regulating and controlling the phase separation capacity of the protein has relatively high controllability and biocompatibility.

Nanolipoprotein particles having at least a scaffold protein component and a membrane lipid component and related compositions, methods and systems are described. The membrane lipid component includes at least one or more membrane forming lipids, one or more polymerized lipids and / or one or more polymerizable lipids.

A macromolecular interaction regulator screening method, comprising the steps of: providing an engineered cell, the cell containing a target condensate A having dynamic fluidity, the target condensate A containing a first fusion protein formed by a target molecule X, a phase separation scaffold protein Y and a first fluorescent protein F1 module, the cell further co-expressing a second fusion protein, and the second fusion protein being a fusion protein formed by a target molecule B and a second fluorescent protein F2 module; by means of interaction of the target molecule X and the target molecule B, forming a condensate complex A-B; in the presence or absence of a candidate compound, separately performing photobleaching treatment on the cell, and measuring fluorescence signals obtained before and after the photobleaching treatment of the condensate complex A-B in the cell; and performing comparison for the change of the fluorescence signals, and evaluating the impact of the candidate compound on the interaction of the target molecule X and the target molecule B.

Nanolipoprotein particles having at least a scaffold protein component and a membrane lipid component and related compositions, methods and systems are described. The membrane lipid component includes at least one or more membrane forming lipids, one or more polymerized lipids and / or one or more polymerizable lipids.

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

The invention relates to an engineered extracellular vesicle with an anti-inflammatory effect and a preparation method of the engineered extracellular vesicle. The engineered extracellular vesicle comprises an extracellular vesicle, an arginase 1 mutant located in a cavity of the extracellular vesicle, an internal support protein for connecting the arginase 1 mutant with the extracellular vesicle, and an external support protein for connecting the internal support protein with the extracellular vesicle, the arginase 1 mutant comprises an arginase 1 protein and a trimer tag, the C end of the arginase 1 protein is connected with the trimer tag, and the N end of the arginase 1 protein is connected with the C end of an endogenous scaffold protein. The engineered extracellular vesicle disclosed by the invention is high in loading efficiency and good in delivery effect, has multi-target activity and has an enhanced broad-spectrum anti-inflammatory effect.

The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46 to 47, 49 to 50, 52 to 53, 55 to 58, 63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1; characterized in that said polypeptide comprises one or mutations relative to SEQ ID NO: 1. The invention also relates to various methods and nucleic acids.

This invention relates to antibody-binding lipid nanoparticles comprising antibodies bound to membrane scaffold proteins, and more specifically, to antibody-binding lipid nanoparticles comprising lipids and antibodies bound to membrane scaffold proteins, which are therefore easy to prepare and have excellent specific targeting capabilities.

The invention discloses a bone targeting exosome polypeptide delivery system based on a biological orthogonal strategy and a preparation method and application thereof, and relates to the technical field of biological medicine and drug delivery. The bone targeting exosome polypeptide delivery system based on the biological orthogonal strategy comprises an engineered exosome as a carrier and an osteogenesis-promoting therapeutic polypeptide, wherein the osteogenesis-promoting therapeutic polypeptide is anchored on the membrane surface of the engineered exosome; a fusion protein is displayed on the membrane surface of the engineered exosome, and the fusion protein is formed by fusing a bone targeting ligand and an industrial exosome transmembrane scaffold protein; the osteogenesis-promoting therapeutic polypeptide is connected with the industrial exosome through the flexible spacer arm, and the membrane surface steric hindrance is reduced through the flexible spacer arm so as to improve the accessibility of the active fragment of the polypeptide; the delivery system provided by the invention can improve the targeted enrichment and treatment efficiency of osteogenesis promoting drugs in bone tissues, and is suitable for intervention of bone metabolism related diseases such as osteoporosis, delayed fracture healing, bone defects and the like.

Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) domain with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, methods of making thereof, and uses as therapeutic molecules for treatment and diagnosis of diseases and disorders.

The invention belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, and relates to a preparation method and application of a co-assembled nano preparation for targeting glioblastoma. The preparation method comprises the following steps: firstly, synthesizing a nitroimidazole dimer with tumor hypoxia-oxidation-reduction triple response, and assembling the nitroimidazole dimer with AOH1996 and HRO761 to prepare the nano preparation. The molar ratio of the AOH1996 to the HRO761 to the nitroimidazole dimer is 1 to 2 to (0.5 to 2). The key scaffold protein PCNA for DNA repair is blocked by the PCNA inhibitor AOH1996, and recruitment and anchoring functions of the key scaffold protein PCNA on repair factors are destroyed, so that the glioblastoma is induced to enter a mismatch repair defect state. On the basis, a WRN inhibitor HRO761 is further used for promoting large-scale breakage of chromosomes and finally inducing cell death. The nitroimidazole dimer and the nitroimidazole dimer are jointly assembled into the nano preparation, and accurate drug release is realized in response to a hypoxia state and oxidation and reduction signals overexpressed in a tumor microenvironment, so that the heterogeneity of the tumor microenvironment is overcome.

The invention relates to a method for regulating and controlling the phase separation capacity of protein and application thereof. The method comprises the following steps: mixing a first protein element and a second protein element to obtain a mixture; detecting the phase separation capacity of the mixture; wherein the first protein element comprises an IDR structural domain of the scaffold protein, and the second protein element comprises a self-assembly structural domain of the scaffold protein or the IDR structural domain of the scaffold protein. According to the method, the IDR structural domain of the scaffold protein is used as the first protein element, the self-assembly structural domain of the scaffold protein or the IDR structural domain of the scaffold protein is used as the second protein element, and the first protein element and the second protein element interact with each other, so that the phase separation strength of the protein elements can be accurately regulated and controlled; and physical or chemical factor intervention is not needed, so that the compatibility between the regulation process and the normal physiological function of the cell is ensured. The method for regulating and controlling the phase separation capacity of the protein has relatively high controllability and biocompatibility.

The application discloses application of SCAMP5 in treatment of autism spectrum disorder. The application research proves that, compared with a CON group, VPA-induced ASD rats have significant neurotransmitter release disorder and synapse signal path abnormality in hippocampus, overexpression of SCAMP5 protein can improve abnormal release of Glu, abnormal expression of scaffold protein Homer1b / c and downstream protein IP3R, and meanwhile, can relieve autism-like behaviors, space working memory and synapse development abnormality of ASD rats. The application provides a new target and a new potential drug for treatment of autism spectrum disorder, and provides a new idea for target treatment of ASD by in-depth exploration of potential path in pathogenesis of autism.

The invention discloses a gp130-loaded engineered extracellular vesicle and application thereof, belongs to the technical field of biological medicines, and relates to a medicine, which comprises a scaffold protein EN144 membrane externally hung gp130 protein-loaded engineered extracellular vesicle, the scaffold protein EN144 membrane externally hung gp130 protein-loaded engineered extracellular vesicle, and the gp130 protein-loaded engineered extracellular vesicle. The sequence of the scaffold protein EN144 is SEQ ID NO: 1; according to the present invention, the EN144-EVhgp130 provides the anti-inflammatory effect in a variety of diseases; the consistency of in-vivo and in-vitro research results shows that the EN144-EVhgp130 and the EN144-EVmgp130 can be used for effectively inhibiting the generation of sepsis inflammatory factors on RNA (Ribonucleic Acid) and protein levels; compared with a clinically approved drug TCZ, the EN144-EVhgp130 shows a higher survival rate and more remarkable inflammation improvement in a sepsis mouse model, and the IC50 of the EN144-EVhgp130 is lower than that of the TCZ.

The invention provides a chicken tibia strength character molecular genetic marker, and relates to the technical field of poultry genetic engineering breeding. The molecular genetic marker of the chicken tibia strength character is a 390 site SNP of an intron 5 of a chicken Cas scaffold protein family member 4 gene, the SNP site is located at the 203th site of SEQ ID NO: 1, and the polymorphism of the SNP site is G / A. The genotype of the molecular genetic marker is obtained by carrying out PCR amplification and sequencing on primers F: 5 '-CCGTCATGCCTACAAG-3' and R: 5 '-GGGATGTTTCACGGGAGGA-3'. The molecular genetic marker is applied to chicken tibia intensity character auxiliary selective breeding, and can realize early selection of tibia intensity characters and early elimination of unwanted breeding hens, so that the feeding cost is reduced, and the chicken tibia intensity character breeding progress is accelerated.

The present disclosure relates to a vesicle, the vesicle comprising a fusion protein, the fusion protein comprising: a scaffold protein, the scaffold protein being an EGF-like repeat and discoid domain 3 (EDIL3) or a fragment thereof; and a tag domain. The vesicles carry unique labels, engineered vesicles are separated through a large-scale purification process, and after quality control, the engineered vesicles can be used as standard substances and / or reference substances to be applied to different scenes.

The invention discloses a scaffold protein, a cellulose body, a preparation method of the cellulose body and application of the cellulose body, and the scaffold protein comprises at least one adhesion module; and at least one carbohydrate binding module; wherein the structural domain of the adhesion module is one or more of CL7, IM7, dockerin and cohesin, and the structural domain of the adhesion module is one or more of CL7, IM7, dockerin and cohesin. According to the preparation method of the cellulose body, stable combination between cellulase and a scaffold protein structure and a pichia pastoris industrial host cellulose body with more excellent protein secretion capacity can be integrated, and the cellulose body can be obtained through engineering construction and has the advantage of large capacity.

The present invention relates to a drug delivery carrier based on extracellular vesicles and its application. The drug delivery carrier contains an extracellular vesicle scaffold protein and a recombinant membrane fusion protein. The recombinant membrane fusion protein includes a first fragment and a second fragment. The amino acid sequence of the first fragment is the amino acid sequence shown in SEQ ID NO:5, and the second fragment has n amino acids, and the sequence of the second fragment is the sequence of the first n amino acids at the N-terminus of the amino acid sequence shown in SEQ ID NO:7, where n is an integer between 50 and 200. The efficiency of releasing drug active molecules by the drug delivery carrier of the present invention before reaching lysosomes is significantly improved, and the efficacy of extracellular vesicle-based drugs can be enhanced.

The present disclosure relates to methods of removing lipids (e.g., cholesterol) or preventing lipid accumulation in an eye of an individual (e.g., a human), and methods of preventing or treating an eye disease characterized by lipid accumulation (e.g., age-related macular degeneration) in an individual, such as an eye disease characterized by age-related macular degeneration. The method comprises administering to an eye of an individual an effective amount of a pharmaceutical composition comprising a plurality of nanodisks, wherein the nanodisks comprise a membrane scaffold protein (MSP) and a phospholipid.

The present disclosure provides scaffold proteins that serve as framework regions for different sets of complementarity determining regions (CDRs) from source antibodies, where the source antibodies bind to different epitopes. The scaffold proteins find use in generating antigen binding polypeptides in single chain fragment variable (scFv) antibody format from a variety of antibodies of interest. These antigen binding polypeptides can have one or more advantageous properties as compared to a source antibody, such as, increased affinity, increased stability, increased expression in a cell, increased yield, etc. The sequence of a scaffold protein has a sequence identity of less than 68% to the sequence of the framework regions of the source antibody.

The invention relates to the field of bacterial membrane protein structures. More specifically, the invention relates to lipid nanodiscs compartmentalized by SlyB protein oligomers isolated from the outer membrane of Gram-negative bacteria. More specifically, the invention provides for a SlyB nanodisc structure wherein the SlyB-oligomer forms the membrane scaffold protein belt, which is surrounded by outer saccharolipid moieties anchored to the SlyB proteins, and which encloses a lipid bilayer nanodomain containing one or more phospholipid layers, wherein macromolecules such as (outer) membrane protein molecules may be captured and stabilized. More specifically, methods to produce and isolate chemically defined stable SlyB nanodisc particles are disclosed herein. Finally, the invention relates to the use of said SlyB nanodiscs as a self-adjuvanting vehicle, as part of an immunogenic composition, and provides for novel means for use in eliciting an immune response against macromolecules enclosed in said SlyB nanodiscs, or for use in a vaccine composition.

The present invention relates to one or more binding molecules capable of inducing receptor signaling of a receptor complex under conditions of non-competitive and / or two-site binding to a scaffold protein. The invention also relates to the therapeutic use of said one or more binding molecules in cancer and autoimmune diseases.